Wednesday, September 28, 2016 6:25:42 PM
The analysts offering 12 month price targets for Ekso Bionics Holdings, Inc. have a median target of $17, with a high estimate of $21 and a low estimate of $8. The median estimate represents a 314.63% increase from the last price.
According to Zacks brokerage recommendations, Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)’s Buy count is 0 and Strong Buy is 3 while the number of analysts recommending Sell and Strong Sell are 0 and 0, respectively. Also, the Hold rating count is 0, as of 27 Sep 2016. The analyst recommendations from a month ago are 0 Buy, 2 Strong Buy, 0 Sell, 0 Hold and 0. Strong Sell. Investors might also notice that two months ago the Buy recommendations (0) were less than Sell recommendations (0). The count of Hold ratings in that period was 0. Chicago-based equity research firm Zacks Investment Research has assigned this stock ABR (Average Brokerage Recommendation) of 1, indicating analysts in general look favorably on the company’s future prospects.
Now, the FactSet Research estimate calls for Q3 2016 earnings of US$-0.34. A month ago, analyst EPS consensus estimated earnings of US$-0.29 per share. They were forecasting US$-0.3 per share three months ago. The Q4 2016 consensus earnings estimates for the company have stabilized at US$-0.33 per share. A month ago, they told us to expect earnings of US$-0.29 per share while three months ago their EPS consensus estimate was US$-0.31.
Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) soared 1.99% year-to-date. The shares have slowed down in recent weeks, with their price down about 0% in the past three months. EKSO rose 13.26%, climbed 4.06% and sank 0% in the week, one month and six months, respectively. The most recent short interest data show 0.4% of the company’s stock are short sold. It would take about 0.29 days to cover all short positions. In terms of volatility, it has a beta coefficient of 0 and technical analysis volatility indicator called Average True Range or ATR around 0.2.
Ekso Bionics Holdings, Inc. (EKSO) closed 6.26% above its 200-day moving average and is 6.26% above another chart threshold, its 50-day moving average. The stock stands nearly -1.91% off versus the 52-week high and 18.84% away from the 52-week low. The number of shares currently owned by investors are 20.14 mln.
---
I'm long EKSO
Recent EKSO News
- Ekso Bionics Announces First Quarter 2024 Financial Results • GlobeNewswire Inc. • 04/29/2024 08:05:00 PM
- Ekso Bionics to Report First Quarter 2024 Financial Results on April 29, 2024 • GlobeNewswire Inc. • 04/22/2024 12:00:00 PM
- Ekso Bionics Receives Final Payment Determination for Medicare Reimbursement from the Centers for Medicare & Medicaid Services (CMS) for Ekso Indego Personal • GlobeNewswire Inc. • 04/12/2024 12:00:16 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/04/2024 09:14:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2024 09:08:54 PM
- Ekso Bionics Reports Record Annual Revenue of $18.3 Million • GlobeNewswire Inc. • 03/04/2024 09:05:00 PM
- Ekso Bionics to Report Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024 • GlobeNewswire Inc. • 02/26/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2024 05:16:39 PM
- Ekso Bionics Announces $4.6 Million Registered Direct Offering • GlobeNewswire Inc. • 01/11/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/10/2024 10:23:43 PM
- Ekso Bionics Launches GaitCoach Software for EksoNR • GlobeNewswire Inc. • 01/08/2024 09:05:00 PM
- Ekso Bionics Reports Certain Preliminary Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 01/04/2024 10:05:12 PM
- Ekso Bionics Receives CMS Coding Approval for Ekso Indego Personal • GlobeNewswire Inc. • 12/12/2023 01:00:00 PM
- Ekso Bionics to Participate at Centers for Medicare & Medicaid Services (CMS) Second Biannual 2023 Healthcare Common Procedure Coding System (HCPCS) Public Meeting on Wednesday, November 29 • GlobeNewswire Inc. • 11/16/2023 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2023 09:13:59 PM
- Centers for Medicare & Medicaid Services (CMS) Codifies Medicare Coverage for Ekso Indego Personal • GlobeNewswire Inc. • 11/02/2023 08:01:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 10/26/2023 08:17:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/26/2023 08:10:19 PM
- Ekso Bionics Reports Third Quarter 2023 Revenue Growth of 38% • GlobeNewswire Inc. • 10/26/2023 08:05:00 PM
- Ekso Bionics to Report Third Quarter 2023 Financial Results on October 26, 2023 • GlobeNewswire Inc. • 10/19/2023 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/29/2023 09:23:17 PM
- Ekso Bionics Supports Centers for Medicare & Medicaid Services (CMS) Proposed Rule to Include Personal Exoskeletons within a Medicare Benefit Category • GlobeNewswire Inc. • 09/27/2023 12:00:00 PM
- Ekso Bionics to Participate at the H.C. Wainwright 25th Annual Global Investment Conference • GlobeNewswire Inc. • 09/11/2023 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/19/2023 01:44:10 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM